Opponents of Mass. ballot question legalizing psychedelics declare victory as results roll in
Why, for instance, can the substances produce severe reactions, triggering schizophrenia or mania in ... at one point ...
Promising Schizophrenia Drug, Cobenfy, Will Likely Face Access Challenges
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
Intra-Cellular Therapies' Treatment Reduces Schizophrenia Relapse Risk 63%
Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk ...
Monthly Prescribing Reference17h
Lumateperone Prevents Relapse in Patients With Schizophrenia
Lumateperone, an atypical antipsychotic, is currently approved under the brand name Caplyta for the treatment of schizophrenia in adults.
FiercePharma22h
Intra-Cellular's unstoppable Caplyta nails another trial, this time for relapse prevention in schizophrenia
Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...
Scanning synaptic receptors: New imaging method sheds light on psychiatric disorders
Even though psychiatric disorders such as schizophrenia, bipolar disorder, and autism spectrum disorder (ASD) are quite ...
psychiatryadvisor.com23h
Risk for Sudden Cardiac Death Elevated for Patients With Psychiatric Disorders
Patients with psychiatric disorders have an increased rate of sudden cardiac death (SCD), according to a study published online.